Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 956 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 956 shares of the firm’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $15.31, for a total transaction of $14,636.36. Following the completion of the transaction, the chief financial officer now directly owns 126,658 shares in the company, valued at $1,939,133.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Troy Wichterman also recently made the following trade(s):

• On Thursday, March 21st, Troy Wichterman sold 520 shares of BioLife Solutions stock. The shares were sold at an average price of $17.83, for a total transaction of $9,271.60.
• On Monday, March 11th, Troy Wichterman sold 361 shares of BioLife Solutions stock. The shares were sold at an average price of $17.42, for a total transaction of $6,288.62.
• On Wednesday, February 21st, Troy Wichterman sold 97 shares of BioLife Solutions stock. The shares were sold at an average price of $17.35, for a total transaction of $1,682.95.

BioLife Solutions Stock Up 1.0 %

BLFS opened at $17.19 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.86 and a quick ratio of 1.83. The company’s 50-day moving average is $17.39 and its 200 day moving average is $15.41. BioLife Solutions, Inc. has a fifty-two week low of $8.92 and a fifty-two week high of $24.50. The firm has a market capitalization of $778.71 million, a P/E ratio of -11.31 and a beta of 1.67.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The company had revenue of $32.73 million for the quarter, compared to analyst estimates of $32.70 million. Research analysts expect that BioLife Solutions, Inc. will post -0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group began coverage on shares of BioLife Solutions in a research note on Thursday, April 4th. They issued a “buy” rating and a $22.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.40.

Institutional Trading of BioLife Solutions

Large investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC increased its holdings in BioLife Solutions by 167.2% during the fourth quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 1,020 shares during the last quarter. GAMMA Investing LLC purchased a new stake in BioLife Solutions during the fourth quarter worth about $41,000. Register Financial Advisors LLC purchased a new stake in BioLife Solutions during the first quarter worth about $96,000. Allspring Global Investments Holdings LLC increased its holdings in BioLife Solutions by 88.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 5,324 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in BioLife Solutions by 8.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock worth $216,000 after buying an additional 1,164 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.